MedDataX Logo

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT ID: NCT01493557

Last Updated: 2015-10-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1067 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective and open label study that aims to enroll approximately 1200 patients with non-valvular atrial fibrillation (NVAF) not previously treated with Pradaxa® and free of gastrointestinal symptoms (GIS) for at least 2 weeks prior to enrolment. Approximately 125 sites in North America will be recruited. Patients who report GIS during the 3 month treatment period will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous (IV) Pantoprazole in Erosive Esophagitis

NCT00133770

Esophagitis
COMPLETED PHASE4

Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation

NCT01051388

Cardio-cerebrovascular Disease
COMPLETED PHASE3

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

NCT07141381

Healthy
RECRUITING PHASE1

A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn

NCT00237367

Gastroesophageal Reflux
COMPLETED PHASE4

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

NCT02097329

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pradaxa (dabigaran etexilate)

Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.

Group Type OTHER

Pradaxa (dabigatran etexilate)

Intervention Type DRUG

150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)

Pradaxa and pantoprazole

Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal

Group Type ACTIVE_COMPARATOR

pantoprazole

Intervention Type DRUG

40 mg q.a.m, p.o.

Pradaxa (dabigatran etexilate)

Intervention Type DRUG

150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)

Pradaxa, 30 minutes after a meal

Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal

Group Type ACTIVE_COMPARATOR

Pradaxa, within 30 minutes after a meal

Intervention Type DRUG

Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pantoprazole

40 mg q.a.m, p.o.

Intervention Type DRUG

Pradaxa (dabigatran etexilate)

150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)

Intervention Type DRUG

Pradaxa, within 30 minutes after a meal

Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal

Intervention Type DRUG

Pradaxa (dabigatran etexilate)

150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Documented non-valvular atrial fibrillation (NVAF) for whom Pradaxa® (dabigatran etexilate) is indicated per the current local label, but who have not received treatment with Pradaxa® (dabigatran etexilate), or who have not been started on Pradaxa® (dabigatran etexilate) more than 7 days prior to potential enrolment in the study. NVAF may be documented by 12-lead electrocardiogram, rhythm strip, pacemaker/ implantable cardioverter defibrillator (ICD) electrograms or Holter monitoring
2. Male and female patients, age greater than or equal to 18 years at entry
3. Written, informed consent

Exclusion Criteria

1. History within 2 weeks of any of the following gastrointestinal (GI) disorders: heartburn, indigestion, gastritis, upper abdominal pain or discomfort, or gastroesophageal reflux requiring the use of proton pump inhibitors, histamine-2 receptor blockers or antacids. Patients with nausea and/or vomiting within the 2 weeks are not excluded if the symptoms were clearly associated with a self-limited acute or febrile illness. Short-term use of PPIs, as prophylaxis, in a hospital setting for the prevention of stress ulcers is acceptable. Calcium carbonate supplements for calcium replacement is not exclusionary (as long as these products are being used as calcium supplementation/replacement and are not being used to treat or relieve GIS.)
2. GI bleeding within one year or any history of symptomatic or endoscopically documented gastroduodenal ulcer or diverticulitis, unless the cause has been permanently eliminated by medical therapy or by surgery(e.g., patients with peptic ulcer disease with endoscopically proven cure after therapy or lower GI bleeding due to diverticulosis cured by segmental colectomy are not excluded.)
3. not applicable
4. Contraindication to pantoprazole or other proton pump inhibitors, e.g. omeprazole, lansoprazole, rabeprazole, atnoprazole, esomeprazole
5. Contraindication to Pradaxa® (dabigatran etexilate) or known hypersensitivity to Pradaxa® (dabigatran etexilate) or its excipients
6. Hemorrhagic disorder, bleeding diathesis or active pathological bleeding
7. Need for anticoagulant treatment for disorders other than atrial fibrillation
8. Current treatment with rifampin
9. Creatinine clearance \<15ml/min (in Canada, \<30ml/min), or patients on renal replacement therapy (dialysis)
10. Pre-menopausal women (last menstruation less than or equal to 1 year prior to informed consent) who: are nursing or pregnant, or are of child bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study. Acceptable methods of birth control include abstinence, tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral implantable or injectable contraceptives, double barrier method and vasectomized partner.
11. Patients who have received an investigational drug in the past 30 days or are participating in another drug study
12. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study
13. Any condition the investigator believes would not allow safe participation in the study
14. Contraindication in patients with mechanical heart valves. The use of Pradaxa in the setting of other forms of valvular heart disease, including the presence of a bio-prosthetic valve, is not recommended.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1160.128.1046 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1160.128.1045 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

1160.128.1003 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Site Status

1160.128.1093 Boehringer Ingelheim Investigational Site

Chandler, Arizona, United States

Site Status

1160.128.1067 Boehringer Ingelheim Investigational Site

Hot Springs, Arkansas, United States

Site Status

1160.128.1103 Boehringer Ingelheim Investigational Site

Mesa, California, United States

Site Status

1160.128.1094 Boehringer Ingelheim Investigational Site

Newport Beach, California, United States

Site Status

1160.128.1042 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

1160.128.1005 Boehringer Ingelheim Investigational Site

Colorado Spring, Colorado, United States

Site Status

1160.128.1023 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Site Status

1160.128.1016 Boehringer Ingelheim Investigational Site

Bridgeport, Connecticut, United States

Site Status

1160.128.1066 Boehringer Ingelheim Investigational Site

Bridgeport, Connecticut, United States

Site Status

1160.128.1018 Boehringer Ingelheim Investigational Site

Guilford, Connecticut, United States

Site Status

1160.128.1050 Boehringer Ingelheim Investigational Site

Norwalk, Connecticut, United States

Site Status

1160.128.1057 Boehringer Ingelheim Investigational Site

Waterbury, Connecticut, United States

Site Status

1160.128.1085 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Site Status

1160.128.1111 Boehringer Ingelheim Investigational Site

Atlantis, Florida, United States

Site Status

1160.128.1032 Boehringer Ingelheim Investigational Site

Brandon, Florida, United States

Site Status

1160.128.1021 Boehringer Ingelheim Investigational Site

Coral Springs, Florida, United States

Site Status

1160.128.1027 Boehringer Ingelheim Investigational Site

Daytona Beach, Florida, United States

Site Status

1160.128.1019 Boehringer Ingelheim Investigational Site

Jacksonville, Florida, United States

Site Status

1160.128.1062 Boehringer Ingelheim Investigational Site

Jacksonville, Florida, United States

Site Status

1160.128.1054 Boehringer Ingelheim Investigational Site

Largo, Florida, United States

Site Status

1160.128.1097 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

1160.128.1109 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

1160.128.1087 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

1160.128.1058 Boehringer Ingelheim Investigational Site

Pensacola, Florida, United States

Site Status

1160.128.1007 Boehringer Ingelheim Investigational Site

Port Charlotte, Florida, United States

Site Status

1160.128.1060 Boehringer Ingelheim Investigational Site

Rockledge, Florida, United States

Site Status

1160.128.1096 Boehringer Ingelheim Investigational Site

Columbus, Georgia, United States

Site Status

1160.128.1068 Boehringer Ingelheim Investigational Site

Roswell, Georgia, United States

Site Status

1160.128.1076 Boehringer Ingelheim Investigational Site

Coeur d'Alene, Idaho, United States

Site Status

1160.128.1073 Boehringer Ingelheim Investigational Site

Melrose Park, Illinois, United States

Site Status

1160.128.1048 Boehringer Ingelheim Investigational Site

Winfield, Illinois, United States

Site Status

1160.128.1105 Boehringer Ingelheim Investigational Site

Hammond, Indiana, United States

Site Status

1160.128.1029 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Site Status

1160.128.1079 Boehringer Ingelheim Investigational Site

Overland Park, Kansas, United States

Site Status

1160.128.1008 Boehringer Ingelheim Investigational Site

Baton Rouge, Louisiana, United States

Site Status

1160.128.1025 Boehringer Ingelheim Investigational Site

Auburn, Maine, United States

Site Status

1160.128.1100 Boehringer Ingelheim Investigational Site

Biddeford, Maine, United States

Site Status

1160.128.1041 Boehringer Ingelheim Investigational Site

Columbia, Maryland, United States

Site Status

1160.128.1012 Boehringer Ingelheim Investigational Site

Salisbury, Maryland, United States

Site Status

1160.128.1015 Boehringer Ingelheim Investigational Site

Rochester Hills, Michigan, United States

Site Status

1160.128.1004 Boehringer Ingelheim Investigational Site

Tupelo, Mississippi, United States

Site Status

1160.128.1014 Boehringer Ingelheim Investigational Site

Columbia, Missouri, United States

Site Status

1160.128.1047 Boehringer Ingelheim Investigational Site

Kansas City, Missouri, United States

Site Status

1160.128.1075 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

1160.128.1069 Boehringer Ingelheim Investigational Site

Great Falls, Montana, United States

Site Status

1160.128.1011 Boehringer Ingelheim Investigational Site

Kalispell, Montana, United States

Site Status

1160.128.1092 Boehringer Ingelheim Investigational Site

Lincoln, Nebraska, United States

Site Status

1160.128.1059 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Site Status

1160.128.1039 Boehringer Ingelheim Investigational Site

Elmer, New Jersey, United States

Site Status

1160.128.1035 Boehringer Ingelheim Investigational Site

Flemington, New Jersey, United States

Site Status

1160.128.1036 Boehringer Ingelheim Investigational Site

Albuquerque, New Mexico, United States

Site Status

1160.128.1063 Boehringer Ingelheim Investigational Site

Hawthorne, New York, United States

Site Status

1160.128.1078 Boehringer Ingelheim Investigational Site

Mineola, New York, United States

Site Status

1160.128.1001 Boehringer Ingelheim Investigational Site

Poughkeepsie, New York, United States

Site Status

1160.128.1022 Boehringer Ingelheim Investigational Site

Asheville, North Carolina, United States

Site Status

1160.128.1052 Boehringer Ingelheim Investigational Site

Gastonia, North Carolina, United States

Site Status

1160.128.1071 Boehringer Ingelheim Investigational Site

Statesville, North Carolina, United States

Site Status

1160.128.1091 Boehringer Ingelheim Investigational Site

Gallipolis, Ohio, United States

Site Status

1160.128.1107 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

1160.128.1053 Boehringer Ingelheim Investigational Site

Bend, Oregon, United States

Site Status

1160.128.1033 Boehringer Ingelheim Investigational Site

Hillsboro, Oregon, United States

Site Status

1160.128.1037 Boehringer Ingelheim Investigational Site

Altoona, Pennsylvania, United States

Site Status

1160.128.1034 Boehringer Ingelheim Investigational Site

Camp Hill, Pennsylvania, United States

Site Status

1160.128.1010 Boehringer Ingelheim Investigational Site

Langhorne, Pennsylvania, United States

Site Status

1160.128.1056 Boehringer Ingelheim Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

1160.128.1065 Boehringer Ingelheim Investigational Site

Uniontown, Pennsylvania, United States

Site Status

1160.128.1043 Boehringer Ingelheim Investigational Site

Charleston, South Carolina, United States

Site Status

1160.128.1040 Boehringer Ingelheim Investigational Site

Rapid City, South Dakota, United States

Site Status

1160.128.1006 Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

1160.128.1104 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1160.128.1061 Boehringer Ingelheim Investigational Site

McKinney, Texas, United States

Site Status

1160.128.1090 Boehringer Ingelheim Investigational Site

New Braunfels, Texas, United States

Site Status

1160.128.1082 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

1160.128.1102 Boehringer Ingelheim Investigational Site

Layton, Utah, United States

Site Status

1160.128.1077 Boehringer Ingelheim Investigational Site

Danville, Virginia, United States

Site Status

1160.128.1064 Boehringer Ingelheim Investigational Site

Falls Church, Virginia, United States

Site Status

1160.128.1110 Boehringer Ingelheim Investigational Site

Manassas, Virginia, United States

Site Status

1160.128.1099 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Site Status

1160.128.1160 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

1160.128.1159 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1160.128.1152 Boehringer Ingelheim Investigational Site

Red Deer, Alberta, Canada

Site Status

1160.128.1153 Boehringer Ingelheim Investigational Site

Spruce Grove, Alberta, Canada

Site Status

1160.128.1167 Boehringer Ingelheim Investigational Site

Coquitlam, British Columbia, Canada

Site Status

1160.128.1158 Boehringer Ingelheim Investigational Site

Victoria, British Columbia, Canada

Site Status

1160.128.1154 Boehringer Ingelheim Investigational Site

Saint John, New Brunswick, Canada

Site Status

1160.128.1166 Boehringer Ingelheim Investigational Site

Bay Roberts, Newfoundland and Labrador, Canada

Site Status

1160.128.1151 Boehringer Ingelheim Investigational Site

Brampton, Ontario, Canada

Site Status

1160.128.1168 Boehringer Ingelheim Investigational Site

Cambridge, Ontario, Canada

Site Status

1160.128.1164 Boehringer Ingelheim Investigational Site

Collingwood, Ontario, Canada

Site Status

1160.128.1173 Boehringer Ingelheim Investigational Site

Corunna, Ontario, Canada

Site Status

1160.128.1171 Boehringer Ingelheim Investigational Site

Greater Sudbury, Ontario, Canada

Site Status

1160.128.1156 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

Site Status

1160.128.1157 Boehringer Ingelheim Investigational Site

Kitchener, Ontario, Canada

Site Status

1160.128.1155 Boehringer Ingelheim Investigational Site

London, Ontario, Canada

Site Status

1160.128.1170 Boehringer Ingelheim Investigational Site

Peterborough, Ontario, Canada

Site Status

1160.128.1165 Boehringer Ingelheim Investigational Site

Sarnia, Ontario, Canada

Site Status

1160.128.1169 Boehringer Ingelheim Investigational Site

Sarnia, Ontario, Canada

Site Status

1160.128.1161 Boehringer Ingelheim Investigational Site

Stayner, Ontario, Canada

Site Status

1160.128.1162 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1160.128.1172 Boehringer Ingelheim Investigational Site

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

O'Dea D, Whetteckey J, Ting N. A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran. Cardiol Ther. 2016 Dec;5(2):187-201. doi: 10.1007/s40119-016-0071-5. Epub 2016 Oct 5.

Reference Type DERIVED
PMID: 27709460 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1160.128

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
NCT05923411 COMPLETED PHASE1
A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers
NCT04157881 COMPLETED PHASE4
Emulation of Randomized Clinical Trial in Cardiovascular Disease
NCT06241833 RECRUITING
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
NCT03908593 UNKNOWN PHASE4
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)
NCT06619314 COMPLETED PHASE1
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
NCT07329972 RECRUITING PHASE1
Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
NCT00829738 COMPLETED
Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects
NCT03464058 COMPLETED PHASE1
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
NCT00037570 COMPLETED PHASE2
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.
NCT03137134 COMPLETED PHASE1
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
NCT02555852 COMPLETED
Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU
NCT02290327 COMPLETED PHASE3
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
NCT00312806 COMPLETED PHASE3
Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects
NCT02264106 COMPLETED PHASE1
The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
NCT00303264 COMPLETED PHASE2
A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants
NCT03290703 COMPLETED PHASE1
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
NCT03457727 COMPLETED PHASE1
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
NCT05134350 COMPLETED PHASE1
PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
NCT02569554 COMPLETED PHASE1
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
NCT00206050 COMPLETED PHASE4
A Study to Explore the Effect of Acid-reducing Agents
NCT04935112 COMPLETED PHASE1
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
NCT01477320 COMPLETED NA
A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.
NCT05630677 COMPLETED PHASE1
Primary carE PPi dEprescRibing Trial
NCT05629143 ACTIVE_NOT_RECRUITING PHASE4
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
NCT06217393 ACTIVE_NOT_RECRUITING PHASE3